| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0002-9149(81)90604-4 |
| P698 | PubMed publication ID | 7196685 |
| P2093 | author name string | Savage DD | |
| Maron BJ | |||
| Epstein SE | |||
| Wolfson JK | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| electrocardiography | Q79785 | ||
| hypertrophic cardiomyopathy | Q1364270 | ||
| P304 | page(s) | 252-257 | |
| P577 | publication date | 1981-08-01 | |
| P1433 | published in | American Journal of Cardiology | Q2208417 |
| P1476 | title | Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study | |
| P478 | volume | 48 |
| Q33161569 | A primer on arrhythmias in patients with hypertrophic cardiomyopathy |
| Q78251280 | ACC/AHA Guidelines for Ambulatory Electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in |
| Q33174748 | Acute hemodynamic deterioration during rapid atrial pacing in patients with hypertrophic cardiomyopathy |
| Q39820630 | Ambulatory electrocardiographic monitoring: can we predict sudden death? |
| Q34275552 | American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the Euro |
| Q70797956 | Amiodarone for long-term management of patients with hypertrophic cardiomyopathy |
| Q95780529 | Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet |
| Q61669357 | Apical hypertrophic cardiomyopathy presenting with sustained monomorphic ventricular tachycardia and electrocardiographic changes simulating coronary artery disease and left ventricular aneurysm |
| Q68907811 | Approaches to prevention and early detection of cardiomyopathies: memorandum from a WHO meeting |
| Q40117894 | Arrhythmias in Dilated and Hypertrophic Cardiomyopathy |
| Q33175408 | Arrhythmias in hypertrophic cardiomyopathy |
| Q70654275 | Arrhythmias in patients with mitral valve prolapse. Types, evaluation, and therapy |
| Q33151284 | Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy |
| Q39554961 | Assessment of the risk-benefit ratio for antiarrhythmic drug use. |
| Q33174392 | Autonomic function in hypertrophic cardiomyopathy |
| Q33154505 | Can we predict sudden cardiac death? |
| Q40380089 | Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension and their influences on prognosis. |
| Q36741453 | Cardiac arrhythmias in hypertrophic cardiomyopathy |
| Q71697389 | Cardiac dysrhythmias in children with idiopathic dilated or hypertrophic cardiomyopathy |
| Q44470510 | Cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy with malignant ventricular tachyarrhythmias |
| Q39614106 | Cardiomyopathies and their role in sudden death |
| Q54325876 | Cardiomyopathy and the Use of Implanted Cardio-Defibrillators in Children |
| Q93649153 | Cardiovascular abnormalities in the athlete: recommendations regarding eligibility for competition. Task force III: Hypertrophic cardiomyopathy, other myopericardial diseases and mitral valve prolapse |
| Q33170110 | Cardiovascular evaluation of adolescents and young adults. Salient aspects of the examination |
| Q39725939 | Causes of sudden death in competitive athletes |
| Q36821490 | Clinical and prognostic evaluation of familial hypertrophic cardiomyopathy in two South African families with different cardiac beta myosin heavy chain gene mutations |
| Q53489965 | Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy. |
| Q41928556 | Clinical sustained uniform ventricular tachycardia in hypertrophic cardiomyopathy: association with left ventricular apical aneurysm |
| Q35706096 | Community study of the causes of "natural" sudden death |
| Q74255703 | Comparison of clinical, morphological, and prognostic features in hypertrophic cardiomyopathy between Japanese and western patients |
| Q40404084 | Current approaches in patients with ventricular tachyarrhythmias |
| Q37930066 | Current perspectives in hypertrophic cardiomyopathy: diagnosis, clinical management, and prevention of disability and sudden cardiac death |
| Q40752705 | Current perspectives on sudden cardiac death in hypertrophic cardiomyopathy |
| Q73319403 | Determinant of QT Dispersion in Patients with Hypertrophic Cardiomyopathy |
| Q51536940 | Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy. |
| Q54603783 | Does treatment influence the natural history of patients with hypertrophic cardiomyopathy? |
| Q40991187 | Electrocardiographic predictors in the ESVEM trial: unsustained ventricular tachycardia, heart period variability, and the signal-averaged electrocardiogram |
| Q36623124 | Electrocardiographic predictors of arrhythmic death. |
| Q72705926 | Electrophysiologic consequences of chronic experimentally induced left ventricular pressure overload |
| Q45088259 | Evaluation of a technique to measure heart rate variability in anaesthetised cats. |
| Q33146591 | Evaluation of the athlete who 'goes to ground' |
| Q40380098 | Evidence favoring the hypothesis that ventricular arrhythmias have prognostic significance in left ventricular hypertrophy secondary to systemic hypertension. |
| Q44772159 | Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy |
| Q35770817 | Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy |
| Q70246914 | Hypertrophic cardiomyopathy |
| Q72663923 | Hypertrophic cardiomyopathy |
| Q80172333 | Hypertrophic cardiomyopathy |
| Q82093356 | Hypertrophic cardiomyopathy |
| Q33148719 | Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration |
| Q42205678 | Hypertrophic cardiomyopathy in identical twins |
| Q33175489 | Hypertrophic cardiomyopathy presenting with 3rd-degree atrioventricular block |
| Q44163223 | Hypertrophic cardiomyopathy with extreme increase in left ventricular wall thickness: functional and morphologic features and clinical significance |
| Q68991974 | Hypertrophic cardiomyopathy, ten years' experience |
| Q36492134 | Hypertrophic cardiomyopathy: Prognosis with medical or surgical therapy |
| Q33172595 | Hypertrophic cardiomyopathy: an important cause of sudden death |
| Q34460145 | Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment |
| Q33175046 | Hypertrophic cardiomyopathy: evaluation and treatment of patients at high risk for sudden death |
| Q34244943 | Hypertrophic cardiomyopathy: infants, children, and adolescents |
| Q70254154 | Hypertrophic cardiomyopathy: long-term effects of propranolol versus verapamil in preventing sudden death in "low-risk" patients |
| Q30478725 | Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death |
| Q69695473 | Hypertrophic cardiomyopathy: two-dimensional echocardiographic score versus clinical and electrocardiographic findings |
| Q92225133 | Identification of Myocardial Disarray in Patients With Hypertrophic Cardiomyopathy and Ventricular Arrhythmias |
| Q36860996 | Implications of arrhythmias and prevention of sudden death in hypertrophic cardiomyopathy. |
| Q36756875 | Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia |
| Q41312357 | Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia |
| Q33169695 | Inducible polymorphic ventricular tachycardia and ventricular fibrillation in a subgroup of patients with hypertrophic cardiomyopathy at high risk for sudden death |
| Q80597935 | Late hyperenhancement in gadolinium-enhanced magnetic resonance imaging: comparison of hypertrophic cardiomyopathy patients with and without nonsustained ventricular tachycardia |
| Q96954634 | Left Bundle Pacing for Left Bundle Branch Block and Intermittent Third-Degree Atrioventricular Block in a MYH7 Mutation-Related Hypertrophic Cardiomyopathy With Restrictive Phenotype in a Child |
| Q50783277 | Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. |
| Q67482425 | Left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: increase in gradient after exercise |
| Q77700092 | Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy |
| Q33161896 | Long-term prognosis in children with hypertrophic cardiomyopathy: an analysis of 37 patients aged less than or equal to 14 years at diagnosis |
| Q38285588 | Low dialysate potassium concentration: an overrated risk factor for cardiac arrhythmia? |
| Q38652026 | Low-dose amiodarone for the treatment of arrhythmias in hypertrophic cardiomyopathy |
| Q71131037 | Malignant familial hypertrophic cardiomyopathy in a family with a 453Arg-->Cys mutation in the beta-myosin heavy chain gene: coexistence of sudden death and end-stage heart failure |
| Q69495372 | Management of arrhythmias in heart failure |
| Q40702994 | Management of arrhythmias in hypertrophic cardiomyopathy |
| Q33150554 | Management of hypertrophic cardiomyopathy in children |
| Q60921259 | Modes of death and clinical outcomes in adult patients with hypertrophic cardiomyopathy in Thailand |
| Q40486857 | Molecular basis of hypertrophic and dilated cardiomyopathy |
| Q34028344 | Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy |
| Q42690166 | Non-Sustained Ventricular Tachycardia Episodes Predict Future Hospitalization in ICD Recipients with Heart Failure |
| Q73904916 | Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients |
| Q33940862 | Nonsustained ventricular tachycardia |
| Q34172186 | Nonsustained ventricular tachycardia. A guide to the clinical significance and management |
| Q40821309 | Nonsustained ventricular tachycardia: identification and management of high-risk patients. |
| Q38951500 | Obstruction is unimportant in the pathophysiology of hypertrophic cardiomyopathy |
| Q35874023 | Outer limits of physiologic hypertrophy and relevance to the diagnosis of primary cardiac disease |
| Q44611134 | Patients at risk for cardiac death late after aortic valve replacement |
| Q77368262 | Pediatric myocardial disease |
| Q94202520 | Possibilités de prévention et de détection précoce des myocardiopathies: Mémorandum d'une Réunion de l'OMS |
| Q35655465 | Potential mechanisms of improvement after various treatments for hypertrophic obstructive cardiomyopathy |
| Q38652016 | Potentially lethal ventricular arrhythmias: from mundane to esoteric |
| Q33175795 | Predictors of sudden cardiac death in hypertrophic cardiomyopathy |
| Q74633785 | Predictors of sudden cardiac death in never previously treated patients with essential hypertension: long-term follow-up |
| Q33172497 | Prevalence and prognosis of exercise-induced nonsustained ventricular tachycardia in apparently healthy volunteers |
| Q36247394 | Primary prophylaxis of sudden death in hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and dilated cardiomyopathy |
| Q36838661 | Problems in diagnosis and management of hypertrophic cardiomyopathy |
| Q71550233 | Prognosis of hypertrophic cardiomyopathy: assessment by 123I-BMIPP (beta-methyl-p-(123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography |
| Q39659338 | Prognosis of ventricular arrhythmias in relation to sudden cardiac death: therapeutic implications |
| Q35367410 | Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. |
| Q50609456 | Progression of left ventricular enlargement in patients with hypertrophic cardiomyopathy: incidence and prognostic value. |
| Q44033376 | QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy |
| Q38888427 | Rapid Device-Detected Nonsustained Ventricular Tachycardia in the Risk Stratification of Hypertrophic Cardiomyopathy. |
| Q73682058 | Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy |
| Q48545553 | Relation of left ventricular function and prognosis in hypertrophic cardiomyopathy: an angiographic study |
| Q33173891 | Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy |
| Q37011369 | Risk stratification of sudden cardiac death in hypertrophic cardiomyopathy |
| Q35724692 | Selection of patients and techniques of heart transplantation |
| Q72776352 | Significance of ventricular tachycardia in idiopathic dilated cardiomyopathy: Observations in 35 patients |
| Q33153211 | Spontaneous and induced vasodepressor/vasovagal syncope in hypertrophic cardiomyopathy |
| Q37041256 | Sudden Death: Evaluation and Prevention |
| Q71711873 | Sudden cardiac death |
| Q33173818 | Sudden cardiac death in patients with hypertrophic cardiomyopathy: from bench to bedside with an emphasis on genetic markers |
| Q37766175 | Sudden death in hypertrophic cardiomyopathy |
| Q33145986 | Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. |
| Q33175941 | Sudden death in hypertrophic myocardiopathy |
| Q34138578 | Sudden death in young people due to hypertrophic cardiomyopathy |
| Q40159909 | Surgical management of ventricular tachyarrhythmias |
| Q68194495 | Surgical versus medical therapy of hypertrophic cardiomyopathy: is the perspective changing? |
| Q33144725 | Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy |
| Q73236647 | Symptomatic Ventricular Tachycardia |
| Q43916286 | The Value of Exercise Test, Hotter Monitoring, and Programmed Electrical Stimulation in Detection of Ventricular Arrhythmias in Patients with Hypertrophic Cardiomyopathy |
| Q40795052 | The clinical significance of nonsustained ventricular tachycardia |
| Q40390031 | The clinical significance of nonsustained ventricular tachycardia: current perspectives |
| Q49044226 | The prevalence and the prognostic value of microvolt T-wave alternans in patients with hypertrophic cardiomyopathy. |
| Q34628580 | The prevention of sudden death in hypertrophic cardiomyopathy |
| Q36660387 | The value of oral amiodarone in the treatment of ventricular arrhythmias in heart disease |
| Q37909320 | Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status |
| Q41134540 | Time-domain signal-averaged electrocardiogram in nonischemic ventricular tachycardia |
| Q40109375 | Ventricular Tachycardia-1983 |
| Q34074592 | Ventricular arrhythmias, sudden death, and prevention in patients with hypertrophic cardiomyopathy |
| Q42344482 | Ventricular premature beats--story petrels? |
| Q77220911 | Verapamil therapy in infants with hypertrophic cardiomyopathy |
| Q71228618 | Vulnerability of patients with obstructive hypertrophic cardiomyopathy to ventricular arrhythmia induction in the operating room. Analysis of 17 patients |
| Q74603942 | [Genetic bases of arrhythmias] |
| Q79713797 | [Long term electrocardiography (Holter monitoring)] |
| Q73656203 | [Practice guidelines of the Spanish Society of Cardiology on cardiac arrythmias] |
| Q73507692 | [Sudden death (V). Identification and treatment of patients with hypertrophic cardiomyopathy at risk of sudden death] |
| Q73538106 | [The clinical practice guidelines of the Sociedad Española de Cardiología on cardiomyopathies and myocarditis] |
Search more.